Yonsei Med J.  2015 Sep;56(5):1244-1250. 10.3349/ymj.2015.56.5.1244.

eNOS3 Genetic Polymorphism Is Related to Post-Ablation Early Recurrence of Atrial Fibrillation

• Shim J
• Park JH
• Lee JY
• Uhm JS
• Joung B
• Lee MH
• Ellinor PT
• Pak HN

• KMID: 2163615
• DOI: http://doi.org/10.3349/ymj.2015.56.5.1244

Abstract

PURPOSE
Previous studies have demonstrated an association between eNOS polymorphisms and atrial fibrillation (AF). We sought to determine whether eNOS polymorphisms are associated with AF recurrence after a radiofrequency catheter ablation (RFCA).
MATERIALS AND METHODS
A total of 500 consecutive patients (56+/-11 years, 77% male) with paroxysmal (68%) or persistent (32%) AF who underwent RFCA and 500 age, gender-matched controls were genotyped for the eNOS3 single nucleotide polymorphism (rs1799983). AF recurrence was monitored according to 2012 ACC/AHA/ESC guidelines.
RESULTS
The frequencies of the rs1799983 variant alleles (T) in the case and control group were not significantly different (OR 1.05, 95% CI 0.75-1.46, p=0.798). AF patients with rs1799983 variants were more likely to have coronary artery disease or stroke than those without genetic variant at this gene (31.0% vs. 17.3%, p=0.004). During mean 17 months follow-up, early recurrence of AF (ERAF; within 3 months) and clinical recurrence (CR) of AF were 31.8% and 24.8%, respectively. The rs1799983 variant was associated with higher risk of ERAF (OR 1.71, 95% CI 1.06-2.79, p=0.028), but not with CR. ERAF occurred earlier (11+/-16 days) in variant group than those without variant allele (20+/-25 days, p=0.016). A multiple logistic regression analysis showed that presence of the rs1799983 variant (OR 1.75, 95% CI 1.07-2.86, p=0.026) and persistent AF were independent predictors for ERAF after AF ablation.
CONCLUSION
The rs1799983 variant of the eNOS3 gene was associated with ERAF, but not with CR, after RFCA. eNOS3 gene variants may have a potential role for stratification of post-ablation management.

Keyword

Atrial fibrillation; eNOS gene; catheter ablation; recurrence

MeSH Terms

Aged
Alleles
Atrial Fibrillation/genetics/*surgery
Case-Control Studies
*Catheter Ablation
Coronary Artery Disease
Female
Follow-Up Studies
Genotype
Humans
Logistic Models
Male
Middle Aged
Nitric Oxide Synthase Type III/*genetics
Polymorphism, Single Nucleotide/*genetics
Recurrence
Republic of Korea
Stroke/genetics
Nitric Oxide Synthase Type III

Figure

• 

  Fig. 1 Kaplan-Meier curves of AF free survival between patients with and without the rs1799983 variant within 3 months after RFCA of AF. AF, atrial fibrillation; RFCA, radiofrequency catheter ablation.

Reference

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114:e257–e354.

2. Terasawa T, Balk EM, Chung M, Garlitski AC, Alsheikh-Ali AA, Lau J, et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med. 2009; 151:191–202.

3. Hall JL, Barac A, Benjamin EJ. Genetic mutations as risk predictors of atrial fibrillation recurrence after catheter ablation? J Am Coll Cardiol. 2010; 55:754–757.

4. Shim J, Joung B, Park JH, Uhm JS, Lee MH, Pak HN. Long duration of radiofrequency energy delivery is an independent predictor of clinical recurrence after catheter ablation of atrial fibrillation: over 500 cases experience. Int J Cardiol. 2013; 167:2667–2672.

5. McCabe JM, Smith LM, Tseng ZH, Badhwar N, Lee BK, Lee RJ, et al. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol. 2008; 31:1146–1151.

6. Tamargo J, Caballero R, Gómez R, Delpón E. Cardiac electrophysiological effects of nitric oxide. Cardiovasc Res. 2010; 87:593–600.

7. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Down-regulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002; 106:2854–2858.

8. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 2000; 97:2832–2835.

9. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002; 20:2023–2027.

10. Tao HM, Chen GZ. Endothelial NO synthase gene polymorphisms and risk of ischemic stroke: a meta-analysis. Neurosci Res. 2009; 64:311–316.

11. Bedi M, McNamara D, London B, Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm. 2006; 3:808–812.

12. Fatini C, Sticchi E, Genuardi M, Sofi F, Gensini F, Gori AM, et al. Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. Eur Heart J. 2006; 27:1712–1718.

13. Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2003; 26(1 Pt 2):295–298.

14. Lee SK, Kim SH, Cho GY, Baik I, Lim HE, Park CG, et al. Obesity phenotype and incident hypertension: a prospective community-based cohort study. J Hypertens. 2013; 31:145–151.

15. Lin YJ, Tai CT, Kao T, Chang SL, Wongcharoen W, Lo LW, et al. Consistency of complex fractionated atrial electrograms during atrial fibrillation. Heart Rhythm. 2008; 5:406–412.

16. Stiles MK, Brooks AG, John B, Shashidhar , Wilson L, Kuklik P, et al. The effect of electrogram duration on quantification of complex fractionated atrial electrograms and dominant frequency. J Cardiovasc Electrophysiol. 2008; 19:252–258.

17. Park JH, Pak HN, Kim SK, Jang JK, Choi JI, Lim HE, et al. Electrophysiologic characteristics of complex fractionated atrial electrograms in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2009; 20:266–272.

18. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J. 2010; 31:1344–1356.

19. Pak HN, Oh YS, Lim HE, Kim YH, Hwang C. Comparison of voltage map-guided left atrial anterior wall ablation versus left lateral mitral isthmus ablation in patients with persistent atrial fibrillation. Heart Rhythm. 2011; 8:199–206.

20. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012; 9:632–696.e21.

21. European Heart Rhythm Association (EHRA). European Cardiac Arrhythmia Scoiety (ECAS). American College of Cardiology (ACC). American Heart Association (AHA). Society of Thoracic Surgeons (STS). Calkins H, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007; 4:816–861.

22. Spence MS, McGlinchey PG, Patterson CC, Allen AR, Murphy G, Bayraktutan U, et al. Endothelial nitric oxide synthase gene polymorphism and ischemic heart disease. Am Heart J. 2004; 148:847–851.

23. Li J, Cun Y, Tang WR, Wang Y, Li SN, Ouyang HR, et al. Association of eNOS gene polymorphisms with essential hypertension in the Han population in southwestern China. Genet Mol Res. 2011; 10:2202–2212.

24. Matarin M, Brown WM, Dena H, Britton A, De Vrieze FW, Brott TG, et al. Candidate gene polymorphisms for ischemic stroke. Stroke. 2009; 40:3436–3442.

25. Park KW, You KH, Oh S, Chae IH, Kim HS, Oh BH, et al. Association of endothelial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans. Heart. 2004; 90:282–285.

26. Grubman E, Pavri BB, Lyle S, Reynolds C, Denofrio D, Kocovic DZ. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardiovasc Electrophysiol. 1999; 10:336–342.

27. Ryu K, Li L, Khrestian CM, Matsumoto N, Sahadevan J, Ruehr ML, et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am J Physiol Heart Circ Physiol. 2007; 293:H1231–H1241.

28. Kurotobi T, Iwakura K, Inoue K, Kimura R, Okamura A, Koyama Y, et al. A pre-existent elevated C-reactive protein is associated with the recurrence of atrial tachyarrhythmias after catheter ablation in patients with atrial fibrillation. Europace. 2010; 12:1213–1218.

29. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104:2886–2891.

30. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamasaki H, Kuroki K, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol. 2010; 56:1463–1472.